Literature Review:

AFOI patients receiving Dexmeditomidine and with Mallampati Class IV airways required significantly less intravenous midazolam rescue sedation than placebo users (33.3 percent [4/12] vs. 91.7 percent [11/12]; p0.001), compared to placebo recipients. In all surgical subtypes except breast biopsies, excision of lesions, and plastic surgery, both Dexmeditomidine treatment groups and placebo treatment groups demonstrated statistically significant (p-values not reported) differences in the percentage of patients who did not require intravenous midazolam rescue sedation during MAC, with the exception of breast biopsies, excision of lesions, and plastic surgery, where no statistically significant difference between the Dexmeditomidine treatment groups and placebo.